ID

14944

Description

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02317159

Link

https://clinicaltrials.gov/show/NCT02317159

Keywords

Versions (1)
  1. 5/9/16 5/9/16 -
Uploaded on

May 9, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chronic Myeloid Leukemia NCT02317159

English

Eligibility Chronic Myeloid Leukemia NCT02317159

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age≥18；
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
the new diagnosis of cml patients in six months；
Description

Myeloid Leukemia, Chronic

Data type

boolean

Alias
UMLS CUI [1]
C0023473
no proof of extra-medullary infiltration of leukemia；
Description

Leukaemic infiltration extramedullary

Data type

boolean

Alias
UMLS CUI [1]
C1868812
ecog ps score：0-2；
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
hepatic and renal functions are normal，serum bilirubin≤1.5*uln, serum alt and ast≤2.5*uln, serum cr≤1.5*uln;
Description

Liver function normal | Normal renal function | Serum total bilirubin measurement | Serum Alanine Transaminase tests | AST serum measurement | Creatinine measurement, serum | Upper Limit of Normal

Data type

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0205307
UMLS CUI [2]
C0232805
UMLS CUI [3]
C1278039
UMLS CUI [4]
C0036828
UMLS CUI [5]
C1261155
UMLS CUI [6]
C0201976
UMLS CUI [7]
C1519815
do not receive the treatment of anti-cml；
Description

Therapeutic procedure Against Chronic Myeloid Leukemia

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0521124
UMLS CUI [1,3]
C0023473
subjects signed informed consent form in line with gcp requirements。
Description

Informed Consent | Good Clinical Practice Requirement

Data type

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C2986419
UMLS CUI [2,2]
C1514873
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or lactating women；
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
received tkis any time before；
Description

Tyrosine kinase inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C1268567
failure to control systemic infection or multiple organ failure；
Description

Sepsis Control Unsuccessful | Multiple Organ Failure

Data type

boolean

Alias
UMLS CUI [1,1]
C0243026
UMLS CUI [1,2]
C0243148
UMLS CUI [1,3]
C1272705
UMLS CUI [2]
C0026766
according to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study；
Description

Comorbidity Affecting Patient safety | Compliance behavior Limited

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C1113679
UMLS CUI [2,1]
C1321605
UMLS CUI [2,2]
C0439801
being diagnosed with other malignancies in the prior 12 months；
Description

Malignant Neoplasms Other

Data type

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205394
have a history of neurological or psychiatric disorders, including epilepsy or dementia；
Description

nervous system disorder | Mental disorders | Epilepsy | Dementia

Data type

boolean

Alias
UMLS CUI [1]
C0027765
UMLS CUI [2]
C0004936
UMLS CUI [3]
C0014544
UMLS CUI [4]
C0497327
known or suspected allergy to imatinib；
Description

Hypersensitivity imatinib

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0935989
bsa≤1.5m2；
Description

Body Surface Area

Data type

boolean

Alias
UMLS CUI [1]
C0005902
using other experimental drugs or participating in other clinical trials in the prior one months。
Description

Investigational New Drugs Other | Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0205394
UMLS CUI [2]
C2348568
Back to the top of the page

Similar models

Eligibility Chronic Myeloid Leukemia NCT02317159

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age≥18；
boolean
C0001779 (UMLS CUI [1])
Myeloid Leukemia, Chronic
Item
the new diagnosis of cml patients in six months；
boolean
C0023473 (UMLS CUI [1])
Leukaemic infiltration extramedullary
Item
no proof of extra-medullary infiltration of leukemia；
boolean
C1868812 (UMLS CUI [1])
ECOG performance status
Item
ecog ps score：0-2；
boolean
C1520224 (UMLS CUI [1])
Liver function normal | Normal renal function | Serum total bilirubin measurement | Serum Alanine Transaminase tests | AST serum measurement | Creatinine measurement, serum | Upper Limit of Normal
Item
hepatic and renal functions are normal，serum bilirubin≤1.5*uln, serum alt and ast≤2.5*uln, serum cr≤1.5*uln;
boolean
C0232741 (UMLS CUI [1,1])
C0205307 (UMLS CUI [1,2])
C0232805 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0036828 (UMLS CUI [4])
C1261155 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
C1519815 (UMLS CUI [7])
Therapeutic procedure Against Chronic Myeloid Leukemia
Item
do not receive the treatment of anti-cml；
boolean
C0087111 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C0023473 (UMLS CUI [1,3])
Informed Consent | Good Clinical Practice Requirement
Item
subjects signed informed consent form in line with gcp requirements。
boolean
C0021430 (UMLS CUI [1])
C2986419 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnant or lactating women；
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Tyrosine kinase inhibitor
Item
received tkis any time before；
boolean
C1268567 (UMLS CUI [1])
Sepsis Control Unsuccessful | Multiple Organ Failure
Item
failure to control systemic infection or multiple organ failure；
boolean
C0243026 (UMLS CUI [1,1])
C0243148 (UMLS CUI [1,2])
C1272705 (UMLS CUI [1,3])
C0026766 (UMLS CUI [2])
Comorbidity Affecting Patient safety | Compliance behavior Limited
Item
according to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study；
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C1321605 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
Malignant Neoplasms Other
Item
being diagnosed with other malignancies in the prior 12 months；
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
nervous system disorder | Mental disorders | Epilepsy | Dementia
Item
have a history of neurological or psychiatric disorders, including epilepsy or dementia；
boolean
C0027765 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
C0014544 (UMLS CUI [3])
C0497327 (UMLS CUI [4])
Hypersensitivity imatinib
Item
known or suspected allergy to imatinib；
boolean
C0020517 (UMLS CUI [1,1])
C0935989 (UMLS CUI [1,2])
Body Surface Area
Item
bsa≤1.5m2；
boolean
C0005902 (UMLS CUI [1])
Investigational New Drugs Other | Study Subject Participation Status
Item
using other experimental drugs or participating in other clinical trials in the prior one months。
boolean
C0013230 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial